NPCE · NASDAQ
NeuroPace (NPCE) Stock Price & Fundamentals
NeuroPace (NPCE) closed at $619.55 on Oct 9, 2026, down 1.50% from the previous close of $628.98.
Share price, past year
1Y −15.52%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $619.55 |
| Sep 30, 2026 | $626.24 |
| Aug 31, 2026 | $642.00 |
| Jul 31, 2026 | $616.29 |
| Jun 30, 2026 | $604.17 |
| May 29, 2026 | $637.96 |
| Apr 30, 2026 | $670.82 |
| Mar 31, 2026 | $657.76 |
| Feb 27, 2026 | $654.75 |
| Jan 30, 2026 | $646.07 |
| Dec 31, 2025 | $680.07 |
| Nov 28, 2025 | $666.72 |
| Oct 31, 2025 | $701.26 |
Key statistics
- Market cap
- $21.24B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $102.86M
- Net income (TTM)
- −$19.11M
- Shares outstanding
- 34.3M
- Dividend yield
- —
- 52-week range
- $590.42 – $737.97
NeuroPace's market cap is $21.24B, based on a share price of $619.55 and 34.3M shares outstanding as of Jun 30, 2026.
Financials
NeuroPace reported revenue of $99.99M for fiscal 2025, up 25.13% from fiscal 2024.
NeuroPace reported a net loss of $21.47M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 6 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $99.99M | +25.1% | −$21.47M | −21.5% | −$0.66 | −$11.34M |
| FY2024ended Dec 31, 2024 | $79.91M | +22.1% | −$27.14M | −34.0% | −$0.93 | −$18.26M |
| FY2023ended Dec 31, 2023 | $65.42M | +43.7% | −$32.96M | −50.4% | −$1.27 | −$19.87M |
| FY2022ended Dec 31, 2022 | $45.52M | +0.8% | −$47.08M | −103.4% | −$1.91 | −$37.47M |
| FY2021ended Dec 31, 2021 | $45.18M | +9.8% | −$36.08M | −79.9% | −$2.17 | −$24.96M |
| FY2020ended Dec 31, 2020 | $41.14M | — | −$24.28M | −59.0% | −$117.85 | −$21.67M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $22.83M | −$6.20M | −$0.18 |
| Q1 FY2026ended Mar 31, 2026 | $22.07M | −$6.69M | −$0.20 |
| Q4 FY2025ended Dec 31, 2025 | $30.61M | −$2.73M | — |
| Q3 FY2025ended Sep 30, 2025 | $27.35M | −$3.50M | −$0.11 |
| Q2 FY2025ended Jun 30, 2025 | $19.50M | −$8.65M | −$0.26 |
| Q1 FY2025ended Mar 31, 2025 | $22.52M | −$6.59M | −$0.21 |
| Q4 FY2024ended Dec 31, 2024 | $21.47M | −$5.25M | — |
| Q3 FY2024ended Sep 30, 2024 | $21.06M | −$5.45M | −$0.19 |
Company profile
- Name
- NeuroPace Inc
- Ticker
- NPCE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Surgical & Medical Instruments & Apparatus
- Headquarters
- 455 N. Bernardo Avenue, Mountain View, CA 94043
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001528287
Recent SEC filings
- Aug 11, 2026
- Aug 11, 2026
- Jul 28, 2026
- Jun 8, 2026
- May 12, 2026
- May 12, 2026
- Mar 3, 2026
- Mar 3, 2026
Frequently asked questions
What is NeuroPace's stock price?
NeuroPace (NPCE) closed at $619.55 on Oct 9, 2026, down 1.50% from the previous close of $628.98.
What is NeuroPace's market cap?
NeuroPace's market cap is $21.24B, based on a share price of $619.55 and 34.3M shares outstanding as of Jun 30, 2026.
How much revenue does NeuroPace make?
NeuroPace reported revenue of $99.99M for fiscal 2025, up 25.13% from fiscal 2024.
Does NeuroPace pay a dividend?
Yes. NeuroPace declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from NeuroPace Inc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures